JT: Inhibitory effect of hypertonic mannitol on vasoconstrictor and vasodilator responses of isolated coronary arteries. Am J Physiol 235: H728, 1978 These results suggest that during dipyridamole-induced hyperemia, regional coronary flow and metabolic responses depend upon the status of the arteries supplying the LV region. Regional differences in flow and metabolism occur independent of major changes in heart rate and aortic and LV pressures.
dipyridamole have also conflicted. Uncontrolled trials often suggested potentially beneficial responses in certain patients with chronic angina pectoris or acute myocardial infarction.12 ' 13 Preliminary results also showed that dipyridamole may be useful for patients with smooth muscle spasm resulting in either asthma or gall bladder and renal colic." In a controlled trial in patients with ischemic heart disease, however, dipyridamole induced no consistently detectable beneficial response relative to findings thought secondary to myocardial ischemia. 15 Recently, investigators have suggested that dipyridamole-induced coronary vasodilatation may be useful in assessing the physiologic significance of coronary artery narrowings.'6 18 Noninvasive myocardial imaging techniques showed that dipyridamole-induced coronary vasodilatation separated most LV regions supplied by angiographically normal coronary arteries from regions supplied by narrowed arteries. However, in patients these noninvasive imaging techniques show only relative changes in tracer uptake and have other limitations.I'9 20 Thus, the precise action of dipyridamole on the coronary circulation in patients with coronary disease needs to be more completely defined. Accordingly, we designed this study to further define regional coronary hemodynamic and metabolic responses to dipyridamole in patients with normal and narrowed coronary arteries.
Methods

Patients
The subjects were 13 men (mean age 50 years, range 35-65 years) undergoing cardiac catheterization to further define the cause of chest pain. Committees for protection of human subjects approved the study and each patient gave informed consent. ECG evidence (. 1.0 mm of ST-segment depression) for transient myocardial ischemia was evoked by stress testing in 11 patients. In the other two, the ECG response to stress was normal. Eleven patients were taking propranolol (320 ± 43 mg/day, mean ± SEM).
Cardiac Catheterization
Patients were in a fasting, postabsorptive state, without premedication, when we performed catheterization. Nitroglycerin was withheld for at least 8 hours before study. A #8F Sones catheter was advanced through the right brachial artery to the left ventricle, and pressure recordings were made as the catheter was withdrawn to the aorta. Coronary angiography was performed as described elsewhere.2' 23 After aortic pressure, heart rate and any ECG changes related to coronary angiography returned to baseline values (± 10%), the Sones catheter was replaced by a catheter containing two equisensitive pressure micromanometers (Millar) . This catheter was positioned with one manometer in the left ventricle and the other in the ascending aorta. A #18 Teflon catheter was inserted percutaneously into the left brachial artery to sample arterial blood, and in patient 10 After all catheters were positioned, ECG and aortic and LV pressures were monitored continuously. When monitoring showed that these variables were stable (± 5%), recordings of temperature in the CS and GCV (CS flow [CSF] and GCV flow [GCVF] signals, respectively) were made at 10 and 25 mm/sec with pressure and ECG signals. Blood samples were obtained.
Dipyridamole Period
While aforementioned signals were being recorded at 10 mm/sec, 20 mg of dipyridamole* was injected into the right atrium over 10 seconds. Recording continued for 60-90 seconds after the injection was com- The degree of coronary artery diameter reduction was evaluated by techniques described elsewhere.21 22 When the major artery supplying a LV region had a diameter narrowed . 50%, perfusion of the region was considered potentially abnormal. When no narrowing . 50% was present in the major artery supplying a region, perfusion of the region was considered potentially normal. Experiments in dogs have shown that long and multiple coronary narrowings can alter coronary hemodynamics similar to short or single higher degree diameter narrowings.3337 Therefore, patients were not included if they had long (e.g. > Table 1 summarizes coronary angiographic findings. Patients 1 and 2 had normal angiograms, and patient 3 had no coronary narrowing > 50%. Thus, of the anterior and inferior regions, six regions were considered normal. Patients 4-13 had > 50% narrowing in at least one major artery. Of these 20 possible LV regions, eight were considered normal and 12 abnormal. Thus, a total of 14 normal and 12 abnormal regions were examined. Seven of the normal regions were anterior and seven were inferior. Of the 12 abnormal regions, six were anterior and six inferior. 
Clinical and Electrocardiographic Findings
Three patients reported chest pain after dipyridamole: patient 13 at 1 minute, patient 3 at 7 minutes and patient 6 at 15 minutes. In patient 13 the pain was considered very mild, disappeared spontaneously within 5 minutes and no intervention was taken. In the other two patients, chest pain was considered moderate to severe. Aminophylline (25 mg/min; total dose, 200 mg), which specifically blocks the vasodilator action of dipyridamole,38 was administered at 10 minutes to patient 3, who thus terminated the study early, and to patient 6 at 20 minutes, after completion of the study. These three patients had no consistent change in aortic systolic and LV end-diastolic pressures; these pressure changes averaged 4 mm Hg and 1 mm Hg, respectively. The increase in heart rate averaged 11 beats/min during chest pain. Neither these three patients nor the 10 patients who did not report chest pain had significant ST-segment shifts. No other problems or adverse effects occurred related to either the procedures or dipyridamole administration. Systemic Total LV blood flow (103 ± 7 ml/min), reflected in CSF, increased between 12 and 60 seconds (34 ± 4 seconds) after injection of dipyridamole ( fig. 2) . A CSF increase to 90% of the peak response was observed in seven patients by 1 minute, in four additional patients by 5 minutes and in the remaining two by 10 minutes. Coronary sinus flow increased 51% at 1 minute, and the increase persisted at 5 (53%), 10 (52%) and 15 minutes (39%) (all p < 0.05 vs control; fig. 3 ). Coronary sinus flow measurements 1-15 minutes after dipyridamole were all similar (p = NS). Twenty minutes after dipyridamole, CSF (115 ± 6 ml/min) decreased and was not significantly different from control values. Total coronary resistance was 1.00 ± 0.07 mm Hg/ml/min during the control period and decreased to 0.63 ± 0.05 mm Hg/ml/min 1 minute after dipyridamole (p < 0.05). Total resistance remained decreased to 0.67 ± 0.05, 0.66 ± 0.05 and 0.70 ± 0.05 mm Hg/ml/min at 5, 10 and 15 minutes, respectively, after dipyridamole (all p < 0.05). Values for total coronary resistance were similar 1-15 minutes after dipyridamole (p = NS). At 20 minutes after dipyridamole, total resistance was not significantly different from control (0.89 ± 0.06 mm Hg/ml/min; p = NS).
During the control period, coronary flows ( fig. 3 ) in both normal and abnormal regions were similar (51 ± 6 and 52 ± 5 ml/min, respectively; p = NS). One minute after dipyridamole, flow increased in normal regions (75%). This flow increase persisted at 5 (80%), 10 (88%) and 15 8 (p = NS). After dipyridamole, lactate production was observed in five abnormal regions at 5, 10 and 20 minutes (patients 4, 9 and 13 and in both regions in patient 10 at 5 minutes; patients 5, 9, 10, 12 and 13 at 10 minutes; and patients 4, 8 and 9 and in both regions in patient 10 at 20 minutes) (all p = NS). Lactate production, however, was found more often 5 and 10 minutes after dipyridamole in abnormal regions compared with normal regions (both p < 0.05).
Evidence for Dipyridamole-induced
Redistribution of Coronary Flow
Compared with coronary flow during the control period, inferior regional flow in patients 7, 9, 10 and 13 decreased > 25% during at least one dipyridamole period. In patient 7 this apparent coronary flow reduction involved an angiographically normal region, occurred only at 20 minutes (table 2) and was not associated with lactate production (table 3 ). In contrast, the evidence for a physiologically significant redistribution of coronary flow was stronger in patients 9, 10 and 13, who had angiographically abnormal inferior regions. A decrease in regional coronary flow 25% occurred at 1, 5, 10 and 15 minutes in patient 9, at 10 and 15 minutes in patient 10, and at 1, 5, 10 and 15 minutes in patient 13 (table 2) . At 20 minutes, flow values returned toward control levels in these three patients. There three patients also had lactate production in inferior regions (table 3) coincident with these flow measurements. During these periods when regional coronary flow and sometimes abnormal lactate metabolism suggested physiologically important redistribution of coronary flow, heart rate usually increased slightly and mean aortic pressure changed variably (table 4) . These changes in heart rate and mean aortic pressure were similar to observations in the other patients whose flow measurements did not suggest a dipyridamole-induced redistribution of coronary flow. Discussion Results of this study show that dipyridamole alters blood flow to certain LV regions. In these patients, before dipyridamole, blood flow and oxygen and lactate metabolism were similar in LV regions supplied by coronary arteries that appeared to be normal or abnormal by coronary angiography. Total LV blood flow, reflected in CSF, began to increase 34 seconds (mean) after the i.v. bolus of dipyridamole. After 1 minute, regional coronary flow and resistance values were different when regions supplied by normal and abnormal coronary arteries were identified. This difference in regional coronary flow and resistance responses persisted for 15 minutes. Differences in regional lactate metabolism were detected at 5 and 10 minutes. Total and regional myocardial oxygen uptake did not change. Coronary hemodynamic and metabolic changes observed after dipyridamole were no longer apparent by 20 minutes. These coronary hemodynamic and metabolic changes were accompanied by only very minimal increases in heart rate and decreases in aortic and LV pressures.
Intravenous dipyridamole-induced coronary vasodilatation was used in patients by Albro et al.18 to evaluate the functional significance of coronary narrowings. Myocardial imaging with thallium-201 showed similar regional uptake after both maximal treadmill exercise and dipyridamole administration. They observed much greater increases in heart rate (38%) and decreases in mean blood pressure (6%) than we observed, Differences in blood pressure were probably secondary to enhanced peripheral blood pooling due to changes from supine to standing positions in the study by Albro et al."8 The greater decrease in pressure would be expected to evoke baroreceptormediated increases in heart rate. Our patients, however, remained supine, and most were receiving propranolol. These factors would be expected to attenuate possible reflexly mediated changes in heart rate. Drug administration also differed in the two studies. Albro 40 however, using larger doses of i.v. dipyridamole (i.e., 80-100 mg over approximately 20 minutes39 or 0.6 mg/kg over 5 minutes40 noted adverse effects including chest pain accompanied by reversible ST elevation or ventricular tachycardia and several cases of myocardial infarction. Although no permanent or serious adverse effects were observed in our study and others,"' 18 caution seems appropriate when administering this agent in large doses to patients with suspected coronary artery disease.
In patients described here, dipyridamole appeared to have a proportionately greater effect on coronary flow than on some hemodynamic determinants of myocardial oxygen consumption. The minimal increase in heart rate was probably offset by reduced LV systolic pressure, because neither total nor regional myocardial oxygen uptake changed in the entire group. In this regard, dipyridamole may be useful in studying the relationship between coronary flow and ventricular function in man. Some animal experiments, using isolated heart models, showed evidence for increased function during periods of increased coronary flow.4" 42 We are currently conducting a more detailed investigation into the effects of dipyridamole-induced increased coronary flow on LV hemodynamic function in man.
After dipyridamole was administered, regional lactate metabolism was altered in several patients. In regions supplied by abnormal coronary arteries, lactate production occurred during the control period in three patients and after dipyridamole in seven patients. In angiographically normal regions, lactate was not produced during the control period and after dipyridamole, it occurred only once. There was an association between lactate production and chest pain only in patient 13. These data suggest that in some angiographically abnormal regions, dipyridamole was detrimental to lactate metabolism. Lactate production is probably an early ischemic event, and lack of changes in LV end-diastolic pressure or significant ST-segment shifts and development of chest pain were not necessarily expected.34 'I Animal experiments have shown that in certain situations, some coronary vasodilators,44-4" including dipyridamole,3' 7, 11 cause redistribution of flow away from one region toward another. The region in which flow was reduced had been supplied by a coronary artery with a high degree of narrowing. This potentially deleterious "steal" phenomenon, to our knowledge, has not previously been documented in humans, but could be inferred from adverse effects after large parenteral doses of dipyridamole.39 40 In patients 9, 10 and 13 we found reasonable evidence that flow was redistributed away from an LV region ( fig. 6 ). In these patients, inferior regional flow decreased after dipyridamole and returned toward control values by 20 Therefore, the variability in flow values found in this study was not surprising and could be explained by varied interpatient responsiveness and degrees of coronary narrowing and the potential for angiographic measurements to be imprecise.
Another potential limitation is that we divided the LV into only two regions, so our results could reflect only average changes occurring within relatively large myocardial areas. Heterogeneity within certain anterior or inferior LV regions relative to flow or metabolic findings would probably be responsible for some of the variability in data when trying to separate potentially normal and abnormal regions. Division of the LV into anterior and inferior regions with GCV and CS sampling deserves further comment. We recognize that the definition of the inferior region is questionable. Depending on the exact position of the coronary venous catheter in the CS, the CS thermistor and CS sampling may miss a portion of the posterior descending contribution. In addition, portions of the anterior region circulation may be sensed only by the proximal (CS) thermistor. The net gain in intravascular volume secondary to repeated blood flow measurements may have partially attenuated some hemodynamic changes related to dipyridamole, perhaps limiting the decrease in blood pressure due to dipyridamole-induced peripheral vasodilatation. Effects of concurrent propranolol, taken by 11 of our 13 patients, may have also altered responses to dipyridamole by both the coronary and systemic circulations. Dipyridamole could also have affected coronary venous drainage.
In conclusion, intravenously administered dipyridamole causes prompt coronary vasodilatation in man and results in increased flow, predominantly to regions supplied by coronary arteries without angiographically significant narrowing. Coincident with these changes in regional flow, myocardial metabolism is also altered. Regional lactate metabolism responses to dipyridamole differed in LV regions supplied by coronary arteries with and without significant narrowings. Total and regional myocardial oxygen uptake values were unchanged. These results further define the effect of dipyridamole on the human coronary circulation.
